Prospective Follow-up Study of the Aortic Diameter in Patients With Giant Cell Arteritis
Last updated on April 2022Recruitment
- Recruitment Status
- Recruiting
Inclusion Criteria
- patients with a previous diagnosis of giant cell arteritis, in whom a yearly computed tomography of the aorta is available can opt to participate in this study
- patients with a first episode of biopsy and/or scintigraphy proven giant cell arteritis
- informed consent form has to be signed by all patients
- patients with a previous diagnosis of giant cell arteritis, in whom a yearly computed tomography of the aorta is available can opt to participate in this study
- patients with a first episode of biopsy and/or scintigraphy proven giant cell arteritis
- informed consent form has to be signed by all patients
Exclusion Criteria
- patients already treated with steroids before performance of PET-scintigraphy
- earlier episodes of giant cell arteritis, without documentation of the aortic diameter at that moment
- patients already treated with steroids before performance of PET-scintigraphy
- earlier episodes of giant cell arteritis, without documentation of the aortic diameter at that moment
Summary
- Conditions
- Giant Cell Arteritis
- Type
- Observational
- Design
- Observational Model: Case-Only
- Time Perspective: Prospective
Participation Requirements
- Age
- Between 50 years and 125 years
- Gender
- Both males and females
Description
As standard care, all patients with a suspicion of GCA undergo a biopsy of the temporal artery and a PET scintigraphy to evaluate the presence of large vessel vasculitis. Patients with proven GCA on biopsy and/or scintigraphy undergo a computed tomography (CT) of the aorta without the administration...
As standard care, all patients with a suspicion of GCA undergo a biopsy of the temporal artery and a PET scintigraphy to evaluate the presence of large vessel vasculitis. Patients with proven GCA on biopsy and/or scintigraphy undergo a computed tomography (CT) of the aorta without the administration of contrast, at diagnosis and yearly thereafter (every 12 +/- 3 months) for 10 years. Measurements include the diameter of the ascending aorta, aortic arch, descending aorta, suprarenal, juxtarenal and infrarenal aorta, and the volume of the thoracic and the abdominal aorta. These measurements are correlated with FDG-uptake at the level of the aorta on PET-scintigraphy at the time of diagnosis. All patients will be treated according to accepted guidelines and standard care in our center (methylprednisolone started at 32 mg/day, with slowly declining doses until stop after 1 to 1,5 years of treatment).
Inclusion Criteria
- patients with a previous diagnosis of giant cell arteritis, in whom a yearly computed tomography of the aorta is available can opt to participate in this study
- patients with a first episode of biopsy and/or scintigraphy proven giant cell arteritis
- informed consent form has to be signed by all patients
- patients with a previous diagnosis of giant cell arteritis, in whom a yearly computed tomography of the aorta is available can opt to participate in this study
- patients with a first episode of biopsy and/or scintigraphy proven giant cell arteritis
- informed consent form has to be signed by all patients
Exclusion Criteria
- patients already treated with steroids before performance of PET-scintigraphy
- earlier episodes of giant cell arteritis, without documentation of the aortic diameter at that moment
- patients already treated with steroids before performance of PET-scintigraphy
- earlier episodes of giant cell arteritis, without documentation of the aortic diameter at that moment
Tracking Information
- NCT #
- NCT01588483
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Daniël Blockmans, MD, PhD University Hospital, Gasthuisberg
- Daniël Blockmans, MD, PhD University Hospital, Gasthuisberg
Get Well Soon